• Revenue: $4.2 million for Q4 2024, including $2.7 million from current revenue and $1.5 million from one-time sale of capital equipment.
• Revenue Growth: 108% increase from $2 million in Q4 2023.
• Gross Margin: 71% in Q4 2024, compared to 52% in Q4 2023.
• Operating Expenses: $11.3 million in Q4 2024, up from $9.8 million in Q4 2023.
• Net Loss: $4.9 million or $0.20 per common share in Q4 2024, a 45% improvement from a net loss of $8.9 million or $0.42 per common share in Q4 2023.
• Cash Position: $54.9 million as of December 31, 2024.

• Warning! GuruFocus has detected 2 Warning Signs with PROF.

Release Date: March 06, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Profound Medical Corp (NASDAQ:PROF) reported a record revenue of $4.2 million for Q4 2024, marking a 108% increase from the same period in 2023.
• The company achieved a gross margin of 71% in Q4 2024, a significant improvement from 52% in Q4 2023.
• Profound Medical Corp (NASDAQ:PROF) reduced its net loss by 45% compared to the same quarter in the previous year.
• The company ended 2024 with a strong cash position of $54.9 million.
• Profound Medical Corp (NASDAQ:PROF) is on track with its captain randomized trial, having met its enrollment target, which could enhance its market position and reimbursement acceptance.

Negative Points

• Total operating expenses increased to $11.3 million in Q4 2024 from $9.8 million in Q4 2023, indicating rising costs.
• Despite improvements, the company still recorded a net loss of $4.9 million for Q4 2024.
• The company did not meet its target of reaching 75 sites by the end of 2024.
• Profound Medical Corp (NASDAQ:PROF) is transitioning to a capital sales model, which may present challenges in predictability and execution.
• There is uncertainty regarding the timing and extent of payments from Medicare and private insurers, which could impact cash flow.

Q & A Highlights

Q: Can you discuss the confidence behind the projected strong growth rates for 2025 and beyond, especially in the context of the new Medicare reimbursement environment? A: Arun Menawat, CEO, explained that the clinical value of their product is well-received, and the economic models show profitability for hospitals due to higher reimbursement rates. The company had a strong Q4 in terms of capital sales, and the sales team is energized. Tom Tamberrino, CCO, added that the Medicare coverage has increased inquiries, and they are pursuing private payers to ensure broader coverage, which supports their growth projections.

Q: What is the status of reaching 75 sites by the end of 2025, and how has the sales model changed? A: Arun Menawat, CEO, acknowledged they did not reach the 75-site target last year but noted growth in the installed base. The company has shifted to a capital plus recurring model, which is where most sales are now. They plan to provide more specific numbers after a few quarters under this new model.

Q: What is the timeline for the launch of the BPH product, and are there any regulatory clearances needed? A: Mathieu Burtnyk, COO, stated that they plan to demo the BPH modules at the AUA meeting, with a mid-year launch timeline. The modules incorporate AI to streamline procedures, and regulatory aspects are part of their project plan for the mid-year launch.

Q: Have you seen an uptake in actual payments through Medicare, and how are private insurance companies responding? A: Arun Menawat, CEO, mentioned that while Medicare payments take time, they have seen an increase in recurring revenue. Some private insurers are paying, sometimes after pre-authorization, and feedback from sites indicates satisfaction with payments received.

Q: Are there specific strategies to target private insurance companies for reimbursement? A: Arun Menawat, CEO, confirmed that they are developing a strategy to prioritize insurance companies, focusing on those already paying and regions with a larger installed base. They are adding specialized personnel to handle this, and while timing is standard, they do not expect major issues.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.